Teva Pharmaceutical Industries (TEVA) Change in Accured Expenses (2025 - 2026)

Teva Pharmaceutical Industries (TEVA) recorded quarterly Change in Accured Expenses of -$144.0 million in Q1 2026, down 251.22% on a QoQ basis from -$41.0 million in Q1 2025, and down 251.22% year-over-year from $95.2 million in Q1 2025.

Teva Pharmaceutical Industries (TEVA) Change in Accured Expenses (2025 - 2026) Analysis & Trends

Teva Pharmaceutical Industries has disclosed Change in Accured Expenses across 2 years of filings, most recently posting -$144.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn -144.00 Mn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn -234.00 Mn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -12.70 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn -14.30 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn -
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 4.89 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 23.00 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn 10.02 Mn
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn 14.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -144.00 Mn
Mar 31, 2026 -144.00 Mn
Mar 31, 2025 -41.00 Mn
Mar 31, 2025 -41.00 Mn